CHICAGO, IL / ACCESS Newswire / April 30, 2025 / Risen Pharma, a clinical stage biotech company focusing on developing treatments that address mechanisms of therapeutic resistance, today announced ...

The study by Li et al. provides fundamental findings supported by convincing evidence that they defined cellular reprogramming of androgen receptor in neuroendocrine prostate cancer (NEPC). The ...

Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25 - Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025 - Cash ...